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InsOBJECTIVES This study sought to determine the effect of radial access on outcomes in women undergoing percuta-
neous coronary intervention (PCI) using a registry-based randomized trial.
BACKGROUND Women are at increased risk of bleeding and vascular complications after PCI. The role of radial access
in women is unclear.
METHODS Women undergoing cardiac catheterization or PCI were randomized to radial or femoral arterial access. Data
from the CathPCI Registry and trial-speciﬁc data were merged into a ﬁnal study database. The primary efﬁcacy endpoint
was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding or vascular complications requiring intervention.
The primary feasibility endpoint was access site crossover. The primary analysis cohort was the subgroup undergoing PCI;
sensitivity analyses were conducted in the total randomized population.
RESULTS The trial was stopped early for a lower than expected event rate. A total of 1,787 women (691 undergoing PCI)
were randomized at 60 sites. There was no signiﬁcant difference in the primary efﬁcacy endpoint between radial or
femoral access among women undergoing PCI (radial 1.2% vs. 2.9% femoral, odds ratio [OR]: 0.39; 95% conﬁdence
interval [CI]: 0.12 to 1.27); among women undergoing cardiac catheterization or PCI, radial access signiﬁcantly reduced
bleeding and vascular complications (0.6% vs. 1.7%; OR: 0.32; 95% CI: 0.12 to 0.90). Access site crossover was
signiﬁcantly higher among women assigned to radial access (PCI cohort: 6.1% vs. 1.7%; OR: 3.65; 95% CI: 1.45 to 9.17);
total randomized cohort: (6.7% vs. 1.9%; OR: 3.70; 95% CI: 2.14 to 6.40). More women preferred radial access.
CONCLUSIONS In this pragmatic trial, which was terminated early, the radial approach did not signiﬁcantly reduce
bleeding or vascular complications in women undergoing PCI. Access site crossover occurred more often in women
assigned to radial access. (SAFE-PCI for Women; NCT01406236) (J Am Coll Cardiol Intv 2014;7:857–67) © 2014 by
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858I schemic heart disease is a leading causeof death among women. Althoughcurrently recommended treatment stra-
tegies such as antithrombotic therapy and
revascularization improve outcomes in pa-
tients with unstable angina and myocardial
infarction (1), they have been studied in pre-
dominantly male populations. Compared
with men, women are at increased risk of
adverse outcomes after acute coronary
syndrome (2) and invasive procedures such
as percutaneous coronary intervention (PCI)
(3). They are also at increased risk of
bleeding complications of both medical ther-
apies for acute coronary syndrome (ACS)
(4) and femoral artery access for PCI (5).Bleeding is the most common complication of PCI
and is associated with increased short- and long-
term morbidity, mortality, and costs (6,7). Using the
radial artery as the access site for PCI signiﬁcantly
decreases bleeding and access site complications
compared with the traditional femoral artery ap-
proach (8), but in contemporary clinical practice,
women are much less likely to undergo transradial
PCI (9).
Women presenting for cardiac catheterization
present a unique challenge because, although they
are at higher risk of femoral arterial access site
bleeding, radial artery access may not be feasible.
Compared with males, females have smaller radial
arteries (10) that may be more prone to spasm, which
is a major cause of radial procedure failure (11). In
addition, women have been signiﬁcantly underrep-
resented in previous studies comparing radial with
femoral access. Thus, the role of radial artery access
in women undergoing PCI remains unclear. Accord-
ingly, we performed a large simple multicenter,
prospective, randomized trial to determine the efﬁ-
cacy and feasibility of transradial PCI in women. Tod interpretation of the data; preparation or approval of the man
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National Cardiovascular Research Infrastructure
(NCRI), a clinical trial infrastructure that incorporates
randomization into an ongoing PCI registry and
serves as a platform for streamlined data collection.METHODS
STUDY DESIGN. The SAFE-PCI for Women trial was a
multicenter, prospective, open-label, randomized,
controlled clinical trial that used the NCRI as the
platform for randomization and data collection. This
was an investigator-initiated trial, the design of
which has been reported previously (12). All trial
management activities including data management
and statistical analyses were performed at the Duke
Clinical Research Institute. Duke University Medical
Center’s Institutional Review Board approved the
study, as did the review Boards of each participating
center. All subjects provided written informed con-
sent before randomization. None of the trial’s funding
sources had a role in the design or implementation of
the study or in the reporting of the data. The authors
wrote all drafts of the manuscript and vouch for the
integrity of and completeness of the data and ana-
lyses. Members of the trial committees are listed
and the trial protocol is given in the Online Appendix.
NATIONAL CARDIOVASCULAR RESEARCH INFRA-
STRUCTURE. The NCRI is an investigator network
created through collaboration between the Duke
Clinical Research Institute and the American College
of Cardiology and funded by the National Heart,
Lung, and Blood Institute (grant 1RC2HL101512-01).
The network includes sites participating in the Na-
tional Cardiovascular Data Registry’s CathPCI Regis-
try, an ongoing PCI registry co-sponsored red by the
American College of Cardiology and the Society for
Cardiovascular Angiography and Intervention. Underuscript; and decision to submit the manuscript for
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859the construct of the NCRI, the data stream of registry-
participating sites is accessed electronically to popu-
late a clinical trial database for patients consented
and enrolled in the SAFE-PCI for Women trial. Patient
demographics, medical history, concomitant medi-
cations, procedure details, and in-hospital clinical
outcomes routinely entered in the registry’s data
collection system using standardized data elements
are transferred to an electronic trial case report form.
Additional trial-speciﬁc information including pro-
cedure information related to vascular access site and
outcomes of interest not obtained as part of the reg-
istry are collected using additional electronic case
report form pages per usual clinical trial standards.
The NCRI computer systems, including randomiza-
tion components, are formally validated, and the in-
tegrated registry and trial-speciﬁc data conform to
the same quality requirements. Because radial access
accounts for a minority of procedures in the United
States (9), initial study sites were identiﬁed through
the CathPCI Registry on the basis of their actual
transradial PCI volume as described previously (12).
Participating sites and principal investigators are lis-
ted in the Online Appendix.
STUDY POPULATION. Women undergoing urgent or
elective PCI or diagnostic cardiac catheterization with
the possibility of PCI were considered eligible for the
trial if they were older than 18 years of age, able to
provide informed consent, and undergoing evalua-
tion or treatment for ischemic heart disease. Exclu-
sion criteria included conditions precluding arterial
access in either the femoral or radial artery (periph-
eral arterial disease severe enough to preclude arte-
rial access, absence of collateral ﬂow in both hands
assessed by use of the Allen or the Barbeau (13) test,
active hemodialysis ﬁstula or graft in an arm to
be used in case of assignment to radial access, inter-
national normalized ratio $1.5 in the presence
of ongoing treatment with vitamin K antagonists,
receipt of an oral factor IIa or Xa inhibitor in the 24 h
before the PCI procedure), known valvular heart dis-
ease requiring valve surgery, planned right heart
catheterization, primary PCI for ST-segment elevation
myocardial infarction (STEMI), known presence of
bilateral internal mammary coronary bypass grafts,
participation in an investigational drug or device
study within 30 days before enrollment, and planned
staged PCI within 30 days after index PCI.
Two patient cohorts were pre-speciﬁed: the total
randomized cohort and the PCI cohort. The total
randomized cohort included all patients randomized
regardless of whether they underwent PCI. The PCI
cohort was a subgroup of the total randomized cohortand included patients who underwent PCI as deﬁned
in the following. The primary analysis of efﬁcacy and
feasibility was performed in the PCI cohort, and a
sensitivity analysis was performed in the total ran-
domized cohort.
RANDOMIZATION. After providing written informed
consent, patients were randomized 1:1 to either radial
or femoral arterial access. Randomization was per-
formed via an online randomization module incor-
porated into the registry trial database.
STUDY PROCEDURES. Patients assigned to radial
access underwent radial artery puncture by either
the counterpuncture technique or the anterior wall
technique (14) on the basis of operator preference.
For femoral arterial access, it was recommended that
operators use either ﬂuoroscopic or ultrasound guid-
ance. Cardiac catheterization and PCI technique was
per operator preference. Adjunctive antithrombotic
therapy was recommended for all transradial pro-
cedures at a minimal dose of 40 IU/kg unfractionated
heparin bolus to minimize the risk of radial artery
occlusion (15). For transfemoral diagnostic pro-
cedures, antithrombotic therapy was at the discretion
of the operator. Bivalirudin was recommended for
PCI in all patients, at a dose per the package insert,
in conjunction with aspirin and an oral P2Y12 inhibi-
tor. Use of glycoprotein IIb/IIIa inhibitors was also
by operator preference.
An immediate post-procedure “patent” hemostasis
technique (16) was recommended for all patients
after radial access; femoral arterial sheaths were
removed $2 h after the discontinuation of bivalirudin
or when the activated clotting time was <150 s if
unfractionated heparin was used for the PCI. Manual
compression or closure devices were permitted at
the operator’s discretion.
ENDPOINTS AND DEFINITIONS. There were 2 pri-
mary endpoints: the primary efﬁcacy endpoint was
bleeding or vascular complications requiring inter-
vention occurring within 72 h of the procedure or
by hospital discharge, whichever came ﬁrst; the pri-
mary feasibility endpoint was access site crossover.
Bleeding was deﬁned according to the Bleeding Aca-
demic Research Consortium (BARC) deﬁnition (17),
and the endpoint of interest for the study included
a composite of BARC type 2, 3, or 5 bleeding
events (deﬁnitions given in the Online Appendix).
Vascular complications included a composite of
arteriovenous ﬁstula, arterial pseudoaneurysm, or
arterial occlusion requiring intervention. Access site
crossover was deﬁned as the inability to complete
the procedure from the assigned arterial access site,
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860requiring conversion from radial to femoral access or
vice versa for procedure completion. Conversions to
the contralateral radial artery in case of assignment
to the radial approach (or contralateral femoral
artery in case of assigned femoral approach) were not
considered access site crossovers. Secondary end-
points included procedure duration, total procedure
radiation dose to the patient measured as air kerma in
milligrays (mGy), total contrast volume used during
the procedure measured in milliliters, and the 30-
day occurrence of death, vascular complications (as
deﬁned previously), or unplanned revascularization.
At 30 days, we also assessed the patient’s access
site preference for their next procedure should the
patient require one. Secondary and 30-day outcomes
were assessed only in patients who underwent PCI. A
clinical events committee adjudicated all suspected
primary efﬁcacy endpoint events.
Because the risk of the primary efﬁcacy endpoint
(bleeding or vascular complications) is dependent
on the combination of intensive anticoagulation
and arteriotomy, a patient was grouped in the PCI
cohort if a coronary guidewire exited the coronary
guide catheter for the purpose of diagnosis or treat-
ment, and systemic antithrombotics were given to
achieve therapeutic levels of anticoagulation. This
included diagnostic procedures such as fractional
ﬂow reserve, intravascular ultrasound, and optical
coherence tomography as well as coronary angio-
plasty and/or stenting.
STATISTICAL ANALYSIS. On the basis of the actual
rate of bleeding events using a deﬁnition approxi-
mating BARC type 2, 3, or 5 bleeding among women
without STEMI undergoing PCI in the CathPCI Reg-
istry, we assumed that the rate of bleeding or vascular
complications in the femoral access arm would be 8%
(18). Using an estimate of bleeding reduction associ-
ated with radial access from observational and
previous clinical trial data (8), we assumed a 50%
decrease in the rate of the primary efﬁcacy endpoint
in the radial access arm. A sample size of 1,576 women
undergoing PCI provided 90% power to detect sta-
tistically signiﬁcant differences at a 2-sided alpha
of 0.05. The sample size was set at 1,800 patients
(900 patients per arm) due to uncertainty in event
rates. Because of the common practice of ad-hoc PCI,
we planned to randomize 3,000 women undergoing
cardiac catheterization to obtain 1,800 undergoing
PCI. No formal power calculation was used for the
primary feasibility endpoint.
After 1,120 patients had been randomized (446
of whom had undergone PCI), an unplanned meeting
of the Data Safety Monitoring Board (DSMB) wasconvened due to a lower than expected rate of the
primary efﬁcacy endpoint. The DSMB recommended
terminating the trial because it was unlikely that
the trial would show a difference between the access
site strategies on the basis of the planned sample size.
There was no evidence of harm in either arm. The
steering committee met to discuss the recommenda-
tion and, because there were no safety issues,
decided to continue enrollment until enrollment in a
quality-of-life substudy was completed (300 patients
undergoing coronary angiography or PCI). The results
of this substudy will be reported separately.
Descriptive summaries of the distribution of
continuous variables are presented as mean  SD, or
median, 25th, 75th percentiles, and subject counts.
Categorical variables are summarized in terms of
frequencies and percentages. The primary analysis of
efﬁcacy and feasibility was performed by modiﬁed
intention-to-treat in the PCI cohort, and sensitivity
analyses of efﬁcacy and feasibility were performed in
the total randomized cohort. Odds ratios for the pri-
mary efﬁcacy and feasibility endpoints were gener-
ated using logistic regression with indicator variables
for randomized assignment, planned use of glyco-
protein IIb/IIIa inhibitors during PCI, and elective
PCI for stable angina versus ACS. Analyses of sec-
ondary endpoints also followed modiﬁed intention-
to-treat principles and were conducted within the
PCI cohort. Secondary analysis of 30-day death, vas-
cular complications, or unplanned revascularization
used the logistic regression and included indicator
variables for randomized assignment, planned use
of glycoprotein IIb/IIIa inhibitors during PCI, and
elective PCI for stable angina versus ACS. Analyses
of secondary continuous outcome measures of pro-
cedure duration, total radiation dose, total contrast
volume were conducted using linear models with a
binary indicator variable for randomized assignment.
Two pre-speciﬁed subgroup analyses for the pri-
mary efﬁcacy endpoint were performed: ACS versus
non-ACS in the PCI cohort and quartiles of site radial
volume in the total randomized cohort. A post-hoc
interaction for the primary efﬁcacy endpoint was
examined in the total randomized cohort between
patients who underwent PCI and those who did not.
We also performed an analysis according to the access
site used to complete the procedure (as treated
analysis) in both the randomized and PCI cohorts.
Exploratory comparisons between the radial and
femoral groups were conducted for 72 h or hospital
discharge bleeding events using the Thrombolysis In
Myocardial Infarction (19) and ACUITY (Acute Cathe-
terization and Urgent Intervention Triage Strategy)
(20) trial deﬁnitions, as well as bleeding and vascular
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861complications that were identiﬁed by sites and re-
ported in the CathPCI Registry. Except for Throm-
bolysis In Myocardial Infarction major, the deﬁnitions
were slightly modiﬁed on the basis of data availability
(Online Appendix). These exploratory endpoints were
reconstructed from events reported by sites and were
not adjudicated. A 2-sided p value # 0.05 was used
for statistical signiﬁcance. All analyses were per-
formed at the Duke Clinical Research Institute using
SAS version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
Between September 2011 and July 2013, 1,787 women
were randomized, 691 (38.7%) of whom underwentFIGURE 1 Randomization and Follow-up
Women undergoing urgent or elective PCI or coronary angiography with
number of patients in each group, the number of patients in each group w
FFR ¼ fractional ﬂow reserve; IVUS ¼ intravascular ultrasound; OCT ¼ oPCI, at 60 sites in the United States; 44 of 62 (70.9%)
activated sites enrolled at least 10 patients. Of the
total randomized cohort, 893 were assigned to radial
access and 894 were assigned to femoral access; of
the PCI cohort, 345 and 346 were assigned to radial
and femoral access, respectively (Fig. 1). Follow-up
for the primary endpoints was available for 99.9% of
the PCI cohort and 99.3% of the total randomized
cohort. Baseline characteristics of the total random-
ized and PCI cohorts are shown in Tables 1 and 2.
There were no signiﬁcant differences between the
randomized groups in either cohort. The majority of
procedures were performed for non–ST-segment
elevation ACS. Unfractionated heparin was given
during the diagnostic catheterization to 65.9% of thethe possibility of PCI were randomized to either radial or femoral arterial access. Shown are the
ho underwent PCI, and the number of patients assessed at 30 days for the secondary endpoint.
ptical coherence tomography; PCI ¼ percutaneous coronary intervention.
TABLE 1 Baseline Characteristics of the Total Randomized Cohort
Radial
(n ¼ 893)
Femoral
(n ¼ 894) p Value
Age, yrs 63.3 (55.1, 72.2) 63.9 (55.7, 72.0) 0.77
BMI, kg/m2 30.5 (26.1, 35.1) 30.8 (26.5, 35.8) 0.29
Current or recent smoking 243 (27.2) 216 (24.2) 0.14
Hypertension 710 (79.5) 714 (79.9) 0.85
Previous MI 160 (17.9) 175 (19.6) 0.37
Previous CABG 40 (4.5) 57 (6.4) 0.08
Hemodialysis 3 (0.3) 3 (0.3) 0.99
Peripheral arterial disease 51 (5.7) 54 (6.0) 0.77
Diabetes mellitus 314 (35.2) 313 (35.0) 0.95
Clinical presentation 0.66
Non-ACS 418 (46.8) 389 (43.5)
NSTEACS 471 (52.7) 503 (56.3)
STEMI 4 (0.4) 2 (0.2)
Values shown are number (%) or median (25th, 75th percentiles).
BMI ¼ body mass index; MI ¼ myocardial infarction; CABG ¼ coronary artery bypass grafting; ACS ¼ acute
coronary syndrome; NSTEACS ¼ non–ST-segment elevation acute coronary syndrome; STEMI ¼ ST-segment
elevation myocardial infarction.
TABLE 2 Baseline Cl
Age, yrs
BMI, kg/m2
Current or recent smok
Hypertension
Previous MI
Previous CABG
Hemodialysis
Peripheral arterial dise
Diabetes mellitus
Clinical presentation
Non-ACS
NSTEACS
STEMI
PCI status*
Elective
Urgent
Emergent
Bivalirudin*
Glycoprotein IIb/IIIa
inhibitor*
Vascular closure device
Values shown are number
ﬂow reserve, intravascula
stenting. †Patients who ha
PCI ¼ percutaneous coro
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862patients assigned to radial access and 25.7% of the
patients assigned to femoral access in the PCI cohort.
Bivalirudin was used as the anticoagulant during PCI
for 59.1% and 65.8% of procedures in the radial andinical and Procedure Characteristics of the PCI Cohort
Radial
(n ¼ 345)
Femoral
(n ¼ 346) p Value
65.1 (56.5, 73.7) 63.9 (56.5, 72.9) 0.32
30.1 (25.9, 34.5) 30.5 (26.9, 35.4) 0.14
ing 106 (30.7) 102 (29.5) 0.72
296 (85.8) 294 (85.0) 0.76
82 (23.8) 96 (27.7) 0.23
25 (7.2) 34 (9.9) 0.22
2 (0.6) 2 (0.6) >0.99
ase 23 (6.7) 29 (8.4) 0.39
144 (41.7) 154 (44.5) 0.46
0.50
98 (28.4) 94 (27.2)
244 (70.7) 251 (72.5)
3 (0.9) 1 (0.3)
0.49
133 (46.5) 123 (43.6)
149 (52.1) 157 (55.7)
4 (1.4) 2 (0.7)
166 (59.1) 181 (65.8) 0.10
32 (11.4) 32 (11.6) 0.93
* 15 (5.1)† 194 (65.5) < 0.001
(%) or median (25th, 75th percentiles). *Excludes patients who underwent fractional
r ultrasound, or optical coherence tomography without coronary angioplasty or
d any femoral arterial access.
nary intervention; other abbreviations as in Table 1.femoral groups, respectively. Vascular closure de-
vices were used for hemostasis in 65.5% of the pa-
tients assigned to femoral access.
The primary efﬁcacy and feasibility outcomes
and secondary outcomes for the PCI and total ran-
domized cohorts are shown in Table 3. The rate of
BARC type 2, 3, or 5 bleeding or vascular complica-
tions requiring intervention in the femoral arm of the
PCI cohort, which was the primary analysis cohort,
was lower than predicted (2.9%). Compared with
femoral access, radial access reduced the primary
efﬁcacy endpoint in this cohort by 60% in the PCI
cohort, which did not reach statistical signiﬁcance.
There were no signiﬁcant interactions noted in the
pre-speciﬁed subgroups of ACS versus non-ACS in
the PCI cohort (Fig. 2). In the total randomized
cohort, radial access signiﬁcantly reduced bleeding
and vascular complications by 70% compared with
femoral access. There was no signiﬁcant interaction
by volume of radial procedures performed at partici-
pating sites; similarly, the post-hoc analysis of the
interaction between patients who underwent PCI and
those who did not was also not signiﬁcant (p ¼ 0.58)
(Fig. 2). With respect to the primary feasibility
endpoint, the rate of conversion to femoral access
from radial access was signiﬁcantly higher than the
rate of conversion to radial access from femoral ac-
cess in both cohorts. Only 1 patient, who was assigned
to femoral access, did not have her diagnostic cathe-
terization procedure successfully completed from
either access site. The major reason for conversion
from radial to femoral access was radial artery spasm
occurring in 42.9% of crossover patients in the PCI
cohort and 43.6% of crossover patients in the total
randomized cohort. Other reasons for access site
crossover are listed in the Online Appendix, as are
the primary efﬁcacy results in the as-treated analysis
in both cohorts, which were similar to the intention-
to-treat results.
Secondary outcomes of procedure duration and
total radiation dose were not statistically different
between the radial and femoral access groups
(Table 4); the mean total contrast volume was signif-
icantly higher among patients assigned to femoral
access. Thirty-day follow-up was available for 582
patients in the PCI cohort (84.2%). The rate of 30-day
death, vascular complications, or unplanned revas-
cularization was not signiﬁcantly different between
the 2 arms. Exploratory analyses using different
bleeding deﬁnitions also showed no signiﬁcant dif-
ferences in either the total randomized or PCI cohort
(Table 5). At 30-day follow-up, 71.9% of patients
assigned to the radial approach preferred radial
access for their next procedure; 23.5% of patients
TABLE 3 Primary Efﬁcacy and Feasibility Endpoints in the Total Randomized
and PCI Cohorts
PCI Cohort
Radial
(n ¼ 345)
Femoral
(n ¼ 345) OR (95% CI) p Value
BARC type 2, 3, or 5 bleeding or
vascular complications
4 (1.2) 10 (2.9) 0.39 (0.12–1.27) 0.12
Type 2 3 (0.9) 6 (1.7)
Type 3 1 (0.3) 4 (1.2)
Type 5 0 0
Arteriovenous ﬁstula 0 0
Arterial pseudoaneurysm 1 (0.3) 0
Arterial occlusion 0 0
Access site crossover 21 (6.1) 6 (1.7) 3.65 (1.45–9.17) <0.01
Total Randomized Cohort
Radial
(n ¼ 891)
Femoral
(n ¼ 884) OR (95% CI) p Value
BARC type 2, 3, or 5 bleeding or
vascular complications
5 (0.6) 15 (1.7) 0.32 (0.12–0.90) 0.03
Type 2 4 (0.4) 10 (1.1)
Type 3 1 (0.1) 4 (0.5)
Type 5 0 0
Arteriovenous ﬁstula 0 0
Arterial pseudoaneurysm 1 (0.1) 1 (0.1)
Arterial occlusion 0 0
Access site crossover 60 (6.7) 17 (1.9) 3.70 (2.14–6.40) <0.01
BARC ¼ Bleeding Academic Research Consortium; CI ¼ conﬁdence interval; OR ¼ odds ratio; PCI ¼ percutaneous
coronary intervention.
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863assigned to the femoral approach preferred femoral
access for their next procedure.
DISCUSSION
The SAFE-PCI for Women trial represents several
“ﬁrsts” for clinical trials. It is the ﬁrst U.S.-based
multicenter, prospective, randomized trial comparing
radial and femoral approaches to cardiac catheteriza-
tion or PCI and is the ﬁrst randomized trial of PCI
strategies performed solely in women. In addition,
it is the ﬁrst registry-based trial in the United
States with patient-level randomization. Importantly,
this registry-trial infrastructure provided several
efﬁciencies in site selection, data collection, and site
workload. Thus, the results and methodology of the
trial inform clinical practice and provide a unique
model for future clinical research.
This study was terminated early at the recom-
mendation of the DSMB on the basis of a lower than
expected rate of bleeding or vascular complications.
Although there was a trend toward beneﬁt, radial
access did not signiﬁcantly reduce bleeding or
vascular complications among women undergoing
PCI. The PCI cohort was essentially a subgroup of the
total randomized cohort in which radial access did
signiﬁcantly reduce bleeding and vascular complica-
tions. Thus, this lack of a signiﬁcant difference may
be due to the limited sample size of women under-
going PCI. There was no signiﬁcant interaction be-
tween patients undergoing PCI and those undergoing
diagnostic catheterization for the primary efﬁcacy
endpoint, suggesting that the beneﬁt of radial access
is consistent across both the PCI and total randomized
cohorts. Although the reduced sample size limits the
statistical certainty of this interpretation, it is
encouraging that the ﬁndings in the total cohort of
women undergoing diagnostic catheterization or PCI
are consistent with the beneﬁts of the radial approach
to bleeding reduction in mixed-sex populations (8).
Also consistent with previous studies was the need to
convert to femoral access from radial, which was
signiﬁcantly higher than the need to convert to radial
access from femoral access. The major reason was
arterial spasm, and the rate of conversion was similar
to that seen in the RIVAL (Radial Versus Femoral
Access for Coronary Intervention) trial, which
included both men and women (21). Future iterations
in PCI catheters and devices, such as improved hy-
drophilic coatings for catheters and extremely
slender 3- and 4-French systems (22), may permit the
application of the radial approach to more women
and reduce access site crossover rates. In addition,
ulnar artery access may also be an alternative ifproven to be as safe as the radial approach. Taken
together with previous studies, the results of the
SAFE-PCI for Women trial suggest that an initial
radial access strategy is reasonable in women under-
going cardiac catheterization or PCI with the recog-
nition that a proportion of patients may require
conversion to femoral access.
Although ischemic heart disease is a leading cause
of mortality in women, they are signiﬁcantly under-
represented in clinical trials. For example, women
have often comprised less than a third of the pop-
ulations of clinical trials of recommended secondary
prevention strategies (23). In addition, trials that have
deﬁned the role of revascularization strategies for
high-risk ACS patients or failure of medical therapy
in stable angina have included mostly men (24,25).
There is reason to believe that women may respond to
treatment strategies differently from men, and it is
clear that women are at signiﬁcantly higher risk of
bleeding with antithrombotic therapy for ACS and
after PCI (18). Such bleeding complications often
occur at the vascular access site and are associated
with subsequent adverse events such as myocardial
infarction, stroke, stent thrombosis, and even death
(26). The majority of PCI procedures in the United
FIGURE 2 Odds Ratios for the Primary Efﬁcacy Endpoint in Subgroups of Patients
Odds ratios for the incidence of Bleeding Academic Research Consortium type 2, 3, or 5 bleeding events or vascular complications requiring
intervention occurring within 72 h of the index PCI or at hospital discharge, whichever occurred ﬁrst. Analysis of the interaction between ACS
and non-ACS patients was performed in the PCI cohort; analysis of the interaction by site radial volume and between patients who underwent
PCI versus those who underwent diagnostic catheterization was performed in the total randomized cohort. Analysis of the interaction between
patients who underwent PCI versus those who underwent diagnostic catheterization was performed post-hoc. ACS ¼ acute coronary syndrome;
PCI ¼ percutaneous coronary intervention.
TABLE 4 Secondary
Procedure duration, mi
Total radiation dose, ai
Total contrast volume,
30-day death, vascular
or unplanned rev
Patient preference for
Radial
Femoral
Either
Values shown are mean  S
in 320 patients assigned to
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864States are performed via femoral artery access (9).
The femoral artery is large and readily accommodates
PCI equipment, and spasm is rare. On the other
hand, hemostasis after femoral access requires the
effect of procedural anticoagulation to wane, thusEndpoints
Radial
(n ¼ 290)
Femoral
(n ¼ 292) p Value
n 51.6  32.3 49.9  30.5 0.46
r kerma, mGy 1,604.0  1,394.0 1,472.3  1,274.1 0.26
ml 152.7  76.9 165.6  82.7 0.03
complications,
ascularization*
15 (5.2) 10 (3.4) 0.26
next procedure†
230 (71.9) 82 (25.7)
26 (8.1) 75 (23.5)
64 (20.0) 162 (50.8)
D or number (%). *Odds ratio: 1.58; 95% conﬁdence interval: 0.71 to 3.48. †Available
radial access and 319 patients assigned to femoral access.necessitating prolonged post-PCI bed rest. In addi-
tion, the femoral artery is deeply situated, particu-
larly in overweight or obese patients, can have
atherosclerotic narrowing, needs relatively intense
manual compression to achieve hemostasis after
PCI, and is difﬁcult to monitor for occult bleeding
such as retroperitoneal hematomas, which are asso-
ciated with increased morbidity and mortality (26).
Several strategies have emerged to reduce the risk
of post-PCI bleeding and are termed “bleeding
avoidance strategies,” which include the direct
thrombin inhibitor bivalirudin, potentially the use of
vascular closure devices, and radial access (27). In
observational studies, radial artery access is associ-
ated with a large reduction in access site bleeding and
major vascular complications compared with femoral
access (8). The radial artery is superﬁcial and readily
compressible and rarely has atherosclerosis. In pa-
tients at high risk of bleeding, such as those with
STEMI, radial access for primary PCI may also reduce
mortality by reducing major bleeding events (28).
TABLE 5 Bleeding Outcomes at 72 H or Hospital Discharge Using
Different Bleeding Deﬁnitions in the Total Randomized Cohort
Radial
(n ¼ 891)
Femoral
(n ¼ 884)
TIMI major 3 (0.3) 5 (0.6)
TIMI minor 3 (0.3) 5 (0.6)
ACUITY major 10 (1.1) 10 (1.1)
CathPCI Registry bleeding 10 (1.1) 12 (1.4)
CathPCI Registry vascular complications 1 (0.1) 1 (0.1)
Events are reconstructed from site-reported events and not adjudicated; see
Online Appendix for deﬁnitions.
TIMI ¼ Thrombolysis In Myocardial Infarction.
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865However, its small caliber can exclude the use of
large-bore catheters in some patients, and arterial
spasm is a major cause of radial access site crossover
necessitating conversion to the femoral approach (11).
Women, in particular, are noted to have smaller
caliber radial arteries than men (10), and thus spasm
may be a more prevalent technical issue. Hence, our
rationale for performing the SAFE-PCI for Women
trial was rooted in the lack of data on radial access
in women and the equipoise that although the
radial approach may reduce post-procedure bleeding,
it may require conversion to femoral access in some
patients.
Performing a study to address this equipoise in
an underrepresented patient subgroup like women
posed several challenges including identifying in-
vestigators with requisite transradial procedure pro-
ﬁciency and the costs of conducting a prospective,
randomized trial (12,29). An important aspect of the
SAFE-PCI for Women trial was the embedding of
the randomization into an ongoing PCI registry. At
the time that enrollment began, radial access
accounted for <10% of PCI procedures performed in
the United States (9). Therefore, it was fundamentally
important to include sites with proﬁciency in the
radial approach. Rather than rely on the traditional
method of using site surveys to determine eligibility,
which is hampered by recall bias, we leveraged the
CathPCI Registry to identify sites using actual trans-
radial procedure volumes. This strategy achieved trial
metrics for enrollment that far exceed traditional
clinical trial operations. More than 96% of sites
enrolled at least 1 patient and nearly 71% of sites
enrolled at least 10 patients. In addition, a large
proportion of the trial case report form was autopo-
pulated with data from the registry, thus reducing
site-level workload. These efﬁciencies in workﬂow
translated into faster enrollment and decreased trial
costs. The overall budget for the SAFE-PCI for
Women trial, which included endpoint adjudicationand a database that is compliant with the U.S. Food
and Drug Administration guidelines on electronic
records (30), was w$5 million, which is far less than a
comparably sized trial would have cost without the
NCRI model. This model is an ideal platform for
more efﬁcient and productive investigational drug or
device studies. Conducting clinical trials for innova-
tive new therapies is increasingly becoming cost
prohibitive; in this context, the NCRI model appears
to be a promising platform for future clinical
investigations (31).
STUDY LIMITATIONS. First, the trial was terminated
early, limiting the statistical power to detect the
effect of radial access on outcomes in women,
particularly in the subgroup of women undergoing
PCI. However, the beneﬁt of the radial access on the
primary efﬁcacy endpoint was also larger than ex-
pected, thus permitting detection of a statistically
signiﬁcant beneﬁt in the total randomized cohort.
Although we used the CathPCI Registry to estimate
the rate of bleeding or vascular complications, the
rate in the trial was much lower than expected. This
low underlying rate of the primary endpoint could
be attributed to vascular access expertise at the
sites that participated in the trial compared with the
other sites in the registry, the Hawthorne effect
(32), the preponderance of bivalirudin use, or a
combination of these factors. Second, the in-
vestigators who participated in the trial were all
experienced in using the radial approach. It is likely
that these results may not translate to novice radial
approach operators who may initially experience
higher rates of conversion to femoral approach.
Studies indicate that although the learning curve for
transradial procedures is not steep (33), operators
interested in adopting radial access may have to
contend with a transient increase in the conversion
to femoral access during the learning phase. Finally,
we excluded patients undergoing primary PCI in our
trial due to the relatively lower overall proﬁciency
with radial approach in the United States at the
time that the trial began, which could have led to
prolonged times to reperfusion. Data that emerged
during the conduct of the SAFE-PCI for Women trial
suggests that transradial primary PCI may lower
mortality compared with the femoral approach (34).
On the basis of the site activity and experience in
the SAFE-PCI for Women trial and the demonstrated
efﬁciency of the NCRI model, a randomized trial
comparing both clinical outcomes and door-to-
balloon time metrics between radial and femoral
access in STEMI patients seems both warranted and
feasible.
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866CONCLUSIONS
In the SAFE-PCI for Women trial that was terminated
early, radial access did not signiﬁcantly lower the
incidence of bleeding or vascular complications in
women undergoing PCI; however, in the larger sam-
ple size of women undergoing cardiac catheterization
or PCI, radial access signiﬁcantly reduced bleeding or
vascular complications. There was a need to convertfrom radial access to femoral access in 6.7% of pa-
tients. As the ﬁrst registry-based, randomized trial
performed in the United States, this study demon-
strates a new paradigm for conducting efﬁcient
pragmatic clinical trials.
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